BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

650 related articles for article (PubMed ID: 24308774)

  • 1. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments.
    Kwok R; Tse YK; Wong GL; Ha Y; Lee AU; Ngu MC; Chan HL; Wong VW
    Aliment Pharmacol Ther; 2014 Feb; 39(3):254-69. PubMed ID: 24308774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
    Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M
    Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography.
    Tsai E; Lee TP
    Clin Liver Dis; 2018 Feb; 22(1):73-92. PubMed ID: 29128062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness.
    Liebig S; Stoeckmann N; Geier A; Rau M; Schattenberg JM; Bahr MJ; Manns MP; Jaeckel E; Schulze-Osthoff K; Bantel H
    Clin Transl Gastroenterol; 2019 Aug; 10(8):e00066. PubMed ID: 31397685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of a novel non-invasive test for diagnosing fibrotic non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease.
    Gao F; Huang JF; Zheng KI; Pan XY; Ma HL; Liu WY; Byrne CD; Targher G; Li YY; Chen YP; Chan WK; Zheng MH
    J Gastroenterol Hepatol; 2020 Oct; 35(10):1804-1812. PubMed ID: 32246876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis.
    Selvaraj EA; Mózes FE; Jayaswal ANA; Zafarmand MH; Vali Y; Lee JA; Levick CK; Young LAJ; Palaniyappan N; Liu CH; Aithal GP; Romero-Gómez M; Brosnan MJ; Tuthill TA; Anstee QM; Neubauer S; Harrison SA; Bossuyt PM; Pavlides M;
    J Hepatol; 2021 Oct; 75(4):770-785. PubMed ID: 33991635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease.
    Cusi K; Chang Z; Harrison S; Lomonaco R; Bril F; Orsak B; Ortiz-Lopez C; Hecht J; Feldstein AE; Webb A; Louden C; Goros M; Tio F
    J Hepatol; 2014 Jan; 60(1):167-74. PubMed ID: 23973932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic review and meta-analysis: non-invasive detection of non-alcoholic fatty liver disease related fibrosis in the obese.
    Ooi GJ; Mgaieth S; Eslick GD; Burton PR; Kemp WW; Roberts SK; Brown WA
    Obes Rev; 2018 Feb; 19(2):281-294. PubMed ID: 29119725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of the index of NASH - ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study.
    Younes R; Rosso C; Petta S; Cucco M; Marietti M; Caviglia GP; Ciancio A; Abate ML; Cammà C; Smedile A; Craxì A; Saracco GM; Bugianesi E
    Liver Int; 2018 Apr; 38(4):715-723. PubMed ID: 29028281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease.
    Castera L
    Semin Liver Dis; 2015 Aug; 35(3):291-303. PubMed ID: 26378645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral?
    Blond E; Disse E; Cuerq C; Drai J; Valette PJ; Laville M; Thivolet C; Simon C; Caussy C
    Diabetologia; 2017 Jul; 60(7):1218-1222. PubMed ID: 28352941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transient elastography with a new probe for obese patients for non-invasive staging of non-alcoholic steatohepatitis.
    Friedrich-Rust M; Hadji-Hosseini H; Kriener S; Herrmann E; Sircar I; Kau A; Zeuzem S; Bojunga J
    Eur Radiol; 2010 Oct; 20(10):2390-6. PubMed ID: 20526777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology and natural history of non-alcoholic fatty liver disease.
    Fazel Y; Koenig AB; Sayiner M; Goodman ZD; Younossi ZM
    Metabolism; 2016 Aug; 65(8):1017-25. PubMed ID: 26997539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noninvasive evaluation of NAFLD.
    Castera L; Vilgrain V; Angulo P
    Nat Rev Gastroenterol Hepatol; 2013 Nov; 10(11):666-75. PubMed ID: 24061203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurements of serum procollagen-III peptide and M30 do not improve the diagnostic accuracy of transient elastography for the detection of hepatic fibrosis in patients with nonalcoholic fatty liver disease.
    Ergelen R; Akyuz U; Aydin Y; Eren F; Yilmaz Y
    Eur J Gastroenterol Hepatol; 2015 Jun; 27(6):667-71. PubMed ID: 25923941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
    Verma S; Jensen D; Hart J; Mohanty SR
    Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods.
    Festi D; Schiumerini R; Marzi L; Di Biase AR; Mandolesi D; Montrone L; Scaioli E; Bonato G; Marchesini-Reggiani G; Colecchia A
    Aliment Pharmacol Ther; 2013 Feb; 37(4):392-400. PubMed ID: 23278163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD.
    Friedrich-Rust M; Romen D; Vermehren J; Kriener S; Sadet D; Herrmann E; Zeuzem S; Bojunga J
    Eur J Radiol; 2012 Mar; 81(3):e325-31. PubMed ID: 22119555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
    Newsome PN; Sasso M; Deeks JJ; Paredes A; Boursier J; Chan WK; Yilmaz Y; Czernichow S; Zheng MH; Wong VW; Allison M; Tsochatzis E; Anstee QM; Sheridan DA; Eddowes PJ; Guha IN; Cobbold JF; Paradis V; Bedossa P; Miette V; Fournier-Poizat C; Sandrin L; Harrison SA
    Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):362-373. PubMed ID: 32027858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of the ELF Test for Detecting Steatohepatitis in Morbid Obese Patients with Suspicion of Nonalcoholic Fatty Liver Disease.
    López IC; Aroca FG; Bernal MDF; Mompeán JAL; Bernal ÁB; Martínez AMH; Barba EM; Velasco JAN; Paricio PP
    Obes Surg; 2017 Sep; 27(9):2347-2353. PubMed ID: 28229316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.